Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis

Colorectal carcinoma (CRC) is one of the most common cancers with considerable metastatic potential, explaining the need for new drug candidates that inhibit tumor metastasis. The signal transducers and activators of the transcription 3 (Stat3) signaling pathway has an important role in CRC and has been validated as a promising anticancer target for CRC therapy. In the present study, we report our findings on nifuroxazide, an anti-diarrheal agent identified as an inhibitor of Stat3. Our studies showed that nifuroxazide decreased the viability of three CRC cell lines and induced apoptosis of cancer cells in a concentration-dependent manner. Moreover, western blot analysis demonstrated that the occurrence of its apoptosis was correlated with the activation of Bax and cleaved caspase-3, and decreased the expression of Bcl-2. In addition, nifuroxazide markedly impaired CRC cell migration and invasion by downregulating phosphorylated-Stat3 Tyr705, and also impaired the expression of matrix metalloproteinases (MMP-2 and MMP-9). Furthermore, our studies showed that nifuroxazide also significantly inhibited the tumor metastasis in lung and abdomen metastasis models of colon cancer. Meanwhile, nifuroxazide functionally reduced the proliferation index, induced tumor apoptosis and impaired metastasis. Notably, nifuroxazide reduced the number of myeloid-derived suppressor cells in the blood, spleens and tumors, accompanied by the increased infiltration of CD8+ T cells in the tumors. Importantly, a marked decrease in the number of M2-type macrophages in tumor in the abdomen metastasis model was also observed. Taken together, our results indicated that nifuroxazide could effectively inhibit tumor metastasis by mediating Stat3 pathway and it might have a therapeutic potential for the treatment of CRC.

Cell Death and Disease (2017) 8, e2534; doi:10.1038/cddis.2016.452; published online 5 January 2017
accumulation of myeloid-derived suppressor cells (MDSCs) and many other tumor-associated immune cells.\textsuperscript{17,18} In case of CRC, existing evidences demonstrate that Stat3 is an important factor related to tumor cell growth, survival, invasion and poor prognosis of human colorectal adenocarcinoma.\textsuperscript{1,4,6} Moreover, activation of Stat3 is correlated with the overexpression of cyclin D1 in CRC. In addition, a significant correlation was also shown between Stat3 and both survivin and Bcl-xl expression in CRC.\textsuperscript{19} Furthermore, increasing evidences demonstrated that knocking down Stat3 expression by specific siRNA or small molecules could suppress the growth of CRC cells \textit{in vitro} and \textit{in vivo}.\textsuperscript{19,20} These data all suggest that Stat3 inhibition provides a rational approach to the treatment of CRC. Although much effort has gone into the development of Stat3 inhibitors and series of Stat3 dimerization inhibitors have been discovered via both computational and experimental methods, so far no Stat3-targeting drug was approved by the Food and Drug Administration.\textsuperscript{21,22}

The development of new safer and more effective drugs is an expensive and time-consuming process, and one solution is to find new uses for existing drugs.\textsuperscript{23,24} Because of the safety profiles and known pharmacokinetics, the existing drugs could be approved by regulatory agencies for human use much faster and easily.\textsuperscript{24} Nifuroxazide is an oral nitrofuran antibiotic that decreases the viability of multiple cancer cells by inhibiting the phosphorylation of Stat3.\textsuperscript{25–27} Moreover, nifuroxazide as an antidiarrheal agent is used elsewhere, although it is not currently approved for use in the United States.\textsuperscript{28} However, the function of nifuroxazide on CRC and its related molecular mechanism have not yet been investigated. Considering the effects of Stat3 in CRC, we hypothesized that nifuroxazide might be useful in the treatment of patients with CRC.

To verify this hypothesis, we evaluated the biological activities of nifuroxazide in CRC \textit{in vitro} and \textit{in vivo}. Our results implied that nifuroxazide could inhibit the viability of CRC cells by inducing apoptosis via the reactive oxygen species (ROS)-mitochondria apoptotic pathway. We also found that nifuroxazide could impair cell migration and invasion. Importantly, nifuroxazide could repress tumor metastasis in the lung and abdomen metastasis models by

Figure 1  Nifuroxazide reduced viability in CRC cancer cells. (a) CRC cell lines CT26, HCT116 and HT29 were treated with different concentrations of nifuroxazide for 24, 48 or 72 h and the cell viability was measured by the MTT assay. Each point represents the mean ± S.D. for at least three independent experiments (*P<0.05, **P<0.01, ***P<0.001 versus vehicle control). (b) The effects of nifuroxazide on colony formation in three CRC cell lines for 12 days; the statistical results of colony formation assays were presented as surviving colonies. Data are expressed as mean ± S.D. from three experiments (*P<0.05, **P<0.01 and ***P<0.001)
reducing immunosuppressive cells and enhancing antitumor immunity. These data suggested that nifuroxazide could be a new agent for the treatment of CRC.

**Results**

**Nifuroxazide inhibited CRC cell proliferation and induced CRC cell apoptosis.** Constitutive Stat3 activation seems to be one of the critical pathways in CRC and is considered to have an important role in CRC carcinogenesis. Moreover, Stat3 phosphorylation at tyrosine residue 705 (Y705, p-Stat3) has high expression in human colon cancer cell lines. To investigate whether nifuroxazide has direct effects on CRC tumor cells, we tested the proliferation inhibition caused by nifuroxazide in HCT116 and HT29 human CRC cell lines, as well as murine CT26 tumor cells by the MTT (3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytenozoliurnromide) assay. Treatment of HCT116, HT29 and CT26 cells with various concentration of nifuroxazide for 24, 48 and 72 h, respectively, resulted in a decrease in the cell viability (Figure 1a). These results suggested that nifuroxazide could inhibit CRC cell viability in a concentration- and time-dependent manner. To further confirm whether nifuroxazide could inhibit viability of CRC, clonogenic assay was performed to visually assess the anti-viability activity of nifuroxazide; the expressions of cleaved caspase-3, Bcl-2 and Bax were determined by western blot with β-actin was used as a standard. (d) The percentage of Bax/Bcl-2 ratio was presented in the bar graphs.

**Figure 2** Nifuroxazide-induced apoptosis of CT26 and HT29 cells. (a) CT26 and HT29 cells were treated with indicated concentrations of nifuroxazide for 24 h, respectively, and then were analyzed by FCM using the Annexin V/PI dual-labeling technique. Each point represents the mean ± S.D. for at least three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001 versus vehicle control). (b) Statistical results of apoptosis assays, including the early apoptotic cells and the late apoptotic cells. Data are expressed as mean ± S.D. from three independent experiments (*P < 0.05, **P < 0.01 and ***P < 0.001). (c) Western blot analyses of CT26 cells treated (24 h) with different concentrations of nifuroxazide; the expressions of cleaved caspase-3, Bcl-2 and Bax were determined by western blot with β-actin was used as a standard. (d) The percentage of Bax/Bcl-2 ratio was presented in the bar graphs.
smaller than the negative control group. Taken together, these results suggested that nifuroxazide had a strong cytostatic and cytotoxic effects on CRC cells.

To examine whether the antiviability activity of nifuroxazide on CRC cells was associated with apoptosis. Hoechst 33358 staining assay showed that nifuroxazide altered the morphology of HCT116, HT29 and CT26 cells and induced apoptosis after 24 h treatment, with the features of a bright blue fluorescent-condensed nuclei and nuclear fragmentation. Besides, these changes were concentration-dependent (Supplementary Figure 1).

To further confirm the induction of apoptosis in HT29 and CT26 cells with nifuroxazide treatment, we also investigated the levels of apoptosis by Annexin V-FITC/PI dual-labeling technique by flow cytometry (FCM). As shown in Figures 2a and b, after nifuroxazide treatment for 24 h, the apoptosis induction effects were observed. When the CT26 cells were treated with 5 μM nifuroxazide, the apoptosis rate was 6.5%, whereas the apoptosis cells increased to 9.3 and 33.2% when cells were treated with 10 and 20 μM nifuroxazide, respectively, indicating that nifuroxazide was able to induce apoptosis in a concentration-dependent manner. Similarly, in HT29 cells, the percentage of apoptotic cells was increased from 4.5 to 13.85% and 60.1% after treatment with various concentration of nifuroxazide for 24 h. The above results implied that the inhibition of CRC cells by nifuroxazide is mediated by the induction of apoptosis.

Nifuroxazide-induced apoptosis via the mitochondria-mediated apoptotic pathway. To further confirm that nifuroxazide-induced tumor cell death was associated with apoptosis, we analyzed the levels of Bcl-2, Bax and cleaved caspase-3 in CT26 cells treated with nifuroxazide using western blot. As shown in Figures 2c and d, the expression of Bcl-2 was significantly reduced, whereas that of Bax and cleaved caspase-3 increased in a concentration-dependent manner, and a significant increase in the ratio of Bax/Bcl-2 was also seen (Figure 2d), suggesting that...
nifuroxazide-induced apoptosis might be via the mitochondrial apoptotic pathway.

To verify the hypothesis, we assessed the changes in the mitochondrial membrane potential (ΔΨm) using a green fluorochrome Rh123 (2-(6-amino-3-imino-3H-xanthen-9-yl) benzoic acid methyl ester) by FCM. As shown in Figure 3a, a significant loss of ΔΨm was observed after nifuroxazide treatment. Moreover, the mitochondria are the major source of ROS generation. In the present study, ROS formation was detected by FCM using an indicator, DCFH-DA. The results showed that the levels of ROS increased after treatment with nifuroxazide (Figure 3b). However, the increased ROS levels were attenuated by treatment with the antioxidant N-acetyl-L-cysteine (NAC) for 1 h (Figure 3c). These results confirmed
that the inhibition of CRC cells by nifuroxazide is mediated by the induction of apoptosis through the mitochondria-mediated apoptotic pathway.

Nifuroxazide impaired cellular migration and invasion. Transwell assays were used to assess the effects of nifuroxazide on cell migration and invasion. As shown in Figures 4a and b, the Transwell migration assay indicated that nifuroxazide significantly inhibited the migration of both HT29 and CT26 cells in a dose-dependent manner (Figures 4c and d). Moreover, Transwell invasion assays assessed the ability of HT29 and CT26 cells to invade through the Matrigel. As shown in Figures 4a and b, both HT29 and CT26 cells exhibit significantly decreased invasion in the presence of nifuroxazide compared with that of vehicle (Figures 4c and d). To further confirm the effects of nifuroxazide on cell migration and invasion, we investigated whether p-Stat3 Tyr705, MMP-2 and MMP-9, which are considered to be associated with cell migration and invasion, were involved in nifuroxazide-mediated cell migration and invasion. The results of western blot indicated that the treatment with nifuroxazide significantly inhibited the expression of p-Stat3, MMP-2 and MMP-9 without affecting the total Stat3 expression level in CT26 cells (Figure 4e). Altogether, all of our results implied that nifuroxazide inhibited the migration and invasion of CRC cells in vitro.

Antimetastasis efficacy of nifuroxazide in vivo. To investigate whether the antitumor activity of nifuroxazide in vivo is consistent with its effects in vitro, two tumor-bearing mice models were established. CT26 cells were injected into Balb/C mice intravenously to establish the lung metastasis model and intraperitoneally to establish the abdominal metastasis model. The mice received the following treatments: vehicle, nifuroxazide at 25 mg/kg and nifuroxazide at 50 mg/kg. In the abdominal implantation model, the abdominal circumference (AC) was calculated from the abdominal anteroposterior diameter before and after treatment, the tumor in the abdominal cavity were removed and weighed, and tumor nodules were counted. As shown in Figures 5a and b, the administration of nifuroxazide resulted in a significant reduction in the weights of tumor nodules and a marked reduction in the number of tumor nodules compared with that of the negative group. In addition, nifuroxazide-treated group significantly reduced splenomegaly compared with control groups (Figure 5c). Furthermore, there was a significant reduction in AC of mice treated by nifuroxazide compared with the vehicle group.

In the lung metastasis model, the lungs were removed, weighed and counted the total number of lung metastatic nodules under the dissection scope. As shown in Figure 5e, the number of lung metastatic nodules was significantly decreased in the nifuroxazide-treated group mice. Moreover, nifuroxazide-treated group had a > 1.8-fold reduction in the weights of the lungs compared with the negative vehicle group. Besides, when given nifuroxazide, it had a ~1.5-fold reduction in the number of metastatic nodules on the lungs compared with the vehicle group (Figure 5f). Overall, these results indicated that the treatment with nifuroxazide almost fully prevented lung metastases.

Nifuroxazide modulated the metastatic environment in the abdominal metastasis model. Previous studies have shown Stat3 as an important molecule in MDSC accumulation in tumor-bearing mice. Moreover, it has been shown that accumulation of MDSCs has a key role in the development of metastasis. Therefore, we examined the number of MDSCs in organs and tumors in the abdominal implantation metastasis model by FCM with CD11b and Gr1 antibody. As shown in Figures 6a and b, the number of CD11b+/Gr1+ MDSCs were significantly decreased in both spleens and peripheral blood after treatment with nifuroxazide compared with vehicle group. In particular, we observed a fourfold reduction in blood infiltration MDSCs in nifuroxazide-treated groups compared with untreated groups (P<0.001). Moreover, we further examined tumor-associated MDSCs infiltration, and from the FCM data, we found ~2.5-fold reduction in MDSCs in the tumor after nifuroxazide treatment (Figure 6c). Furthermore, the tumor infiltration of active CD8+ T lymphocytes was increased in the nifuroxazide-treated group compared with the control group (P<0.01) (Figures 6e and f).

Tumor-associated macrophages are important immune cells that exist in tumor microenvironments and have a role in modulating tumor-associated immune reaction. Moreover, the M2-type macrophages usually have a negative role in anticancer therapy by releasing cytokines that can promote cancer progression. Therefore, we tested the number of M2-type macrophages in tumor by FCM with the surface marker CD11b+ F4/80+ CD206+. As shown in Figures 6g and h, the number of M2-type macrophages were significantly decreased in tumor after treatment with nifuroxazide compared with the vehicle group.

The lung metastatic environment was modulated by nifuroxazide in the lung metastasis model. To further confirm that nifuroxazide could inhibit tumor metastasis, in part, by affecting the tumor microenvironment, we also investigated the changes of immune cells in the lung metastasis model. As shown in Figures 7a and b, we observed ~4-fold reduction of MDSCs in nifuroxazide-treated groups compared with vehicle groups in the blood. However, statistical analysis also demonstrated that nifuroxazide did not significantly decrease the number of MDSC in the spleen and lung compared with that of the vehicle group (data not shown). Then, we determined whether nifuroxazide treatment could reduce the presence of M2-type macrophage cells in the lungs. As shown in Figures 7c and d, the number of M2-type macrophages were significantly decreased in the lungs after treatment with nifuroxazide was observed.

Nifuroxazide inhibited proliferation, induced apoptosis and impaired metastasis in vivo. To define the mechanisms through which nifuroxazide elicited CRC tumor growth inhibition in vivo, immunohistochemistry (IHC) and the western blot analyses were performed in tumor tissues. There is increasing evidence to indicate that MMPs have important roles in tumor invasion and metastasis. We therefore measured the effects of nifuroxazide on the expression of MMP-9 by IHC; as shown in Figures 8a and b, treatment of mice with nifuroxazide inhibited the expression of MMP-9 in CT26 tumor tissues. Moreover, we
also found that treatment with nifuroxazide could inhibit the expression of p-Stat3 in CT26 tumor tissues (Figures 8a and c). Furthermore, western blot analyses of the whole tumor lysates revealed a marked inhibition of p-Stat3 by nifuroxazide treatment (Figure 8f). These results suggest that nifuroxazide has significant antitumor effects in vivo, with at least inhibition of Stat3 signaling pathway. In addition, nifuroxazide significantly induced apoptosis cells of cleaved caspase-3-positive cells and inhibited the proliferation of nuclear Ki-67-positive cells (Figures 8d and e). Our data demonstrated that nifuroxazide could inhibit/reverse early metastasis in CRC, which is consistent with the in vitro data.

Discussion

CRC is one of the most common cancers worldwide with considerable metastatic potential and drug resistance, and the incidence is increasing rapidly. Diverse therapies such as radiation, chemotherapy and immunotherapy have shown beneficial effects, but are limited because of their safety and toxicity.31 There is an urgent need to discover the novel potential drug candidate against CRC. Recent studies have reported constitutive activation of Stat3 signaling pathway in human CRCa. Besides, the level of activated p-Stat3 increased in 45 primary CRC samples compared with adjacent normal mucosae has been reported.6 Therefore, directly inhibiting Stat3 might be a promising novel approach for CRC therapy.

In the present study, nifuroxazide, an oral antidiarrheal agent identified as an inhibitor of Stat3, was evaluated for the first time for its potency against CRC in vitro and in vivo. Our results showed that three CRC cell lines were sensitive to nifuroxazide. In addition, nifuroxazide could inhibit CRC cell viability in a time- and dose-dependent manner, and clonogenicity assay was performed to visually confirm this result. Moreover, in our established abdomen metastasis model, fewer cells that were Ki-67-positive were observed in the tumor tissues treated with nifuroxazide than in the untreated group, indicating that nifuroxazide could inhibit cell proliferation both in vitro and in vivo.

Apoptosis is a major route to eradicate cancer cells and is controlled by a diverse range of cell signals.32 In the intrinsic
apoptosis pathway, the mitochondria have an important role by altering the mitochondrial transmembrane potential. This apoptosis pathway involves the participation of Bcl-2 family proteins, including the proapoptotic protein Bax and the antiapoptotic protein Bcl-2. In this study, Hoechst 33358 staining and FCM assays both revealed that nifuroxazide...
treatment induced apoptosis on CRC cells in a concentration-dependent manner. Moreover, the activation of CC-3 was observed after treatment with nifuroxazide both in vitro and in vivo. Importantly, the occurrence of apoptosis was associated with the activation of Bax and the downregulation of Bcl-2, which also induced a loss of ΔΨm in CT26 cells after

**Figure 6** Nifuroxazide modulated immune cells in the abdominal metastasis model. (a–c) Nifuroxazide significantly reduced tumor-associated MDSCs in the abdominal metastasis model. Flow cytometry analysis quantified CD11b+Gr1+ myeloid cells in peripheral blood after treatment with nifuroxazide. Statistic results of the abdominal metastasis model. Bars show mean ± S.D.; five mice every group (**P < 0.01 and ***P < 0.001). (c and d) M2-type macrophages from tumors were analyzed by flow cytometry for the presence of CD11b+F4/80+CD206+. Bars show mean ± S.D.; three mice every group (**P < 0.01)

**Figure 7** Nifuroxazide modulated MDSCs and M2-type macrophages in the lung metastasis model. (a and b) Nifuroxazide significantly reduced tumor-associated MDSCs in the lung metastasis model. Flow cytometry analysis quantified CD11b+Gr1+ myeloid cells in peripheral blood after treatment with nifuroxazide. Statistic results of the lung metastasis model. Bars show mean ± S.D.; five mice every group (**P < 0.01 and ***P < 0.001). (c and d) M2-type macrophages from lungs were analyzed by flow cytometry for the presence of CD11b+F4/80+CD206+. Bars show mean ± S.D.; three mice every group (**P < 0.01)
nifuroxazide treatment. Furthermore, many studies have shown that disruption of the ROS homeostasis has an important role in mitochondrial dysfunction and apoptotic events. We also found that nifuroxazide significantly increased ROS production in CT26 cells, while the enhanced ROS levels were attenuated by pretreatment with antioxidant

**Figure 8** Nifuroxazide reduced tumor cell proliferation, and induced tumor apoptosis in the abdominal metastasis model. To establish an abdominal metastasis model, a total of 5 x 10^5 CT26 cells were intraperitoneally injected. On day 6 after post-tumor inoculation, mice were treated with 25 and 50 mg/kg per day of nifuroxazide (*P* < 0.05, **P** < 0.01 and ***P*** < 0.001 versus vehicle control). (a and b) The immunohistochemical analysis was performed to measure the expressions of MMP-9 in tumor tissues. *P*-values for comparison of two groups were determined by TWO-tailed Student’s *t*-test. (a and c) The immunohistochemical analysis was performed to measure the expressions of P-Stat3 in tumor tissues. *P*-values for comparison of two groups were determined by TWO-tailed Student’s *t*-test. (d) The statistical data of cleaved caspase-3-positive cell number were shown. (e) The statistical data of Ki-67-positive cell number were shown. (f) The expression of p-Stat3 in the tumor treated or not treated by nifuroxazide by western blot.
NAC, which indicated that the effects of nifuroxazide in CT26 cells may be associated with cell redox system imbalance. Therefore, these results indicated that nifuroxazide treatment induced apoptotic death on CRC through ROS-mediated mitochondrial apoptotic pathway. However, several questions remain: Why were the levels of ROS lower when drug dose was increased (20 μM compared with 10 μM)? Once ROS levels reach a certain degree, is increasing the drug dose helpful for ROS production? Else, does this lead to other side effects and reduce chemotherapy tolerance? Therefore, in-depth studies are still needed to explain this phenomenon.

It has been reported that ~30–50% of CRC patients who undergo curative resection subsequently experience local tumor recurrence or metastasis. Moreover, tumor cell migration and invasion is a key step in successful cancer metastasis, and inhibition of this important step is a practical approach to antitumor treatment. Therefore, the inhibitory effects of nifuroxazide on metastasis were evaluated by cell invasion and migration assays. The Transwell assays indicated that nifuroxazide inhibited HT29 and CT26 cell migration and invasion. Moreover, some cell invasion- and migration-related proteins, such as p-Stat3 Tyr705, MMP-2 and MMP-9, were downregulated by nifuroxazide in CT26 cells. Similar results were observed in the abdominal implantation model, with reduction in the number of MMP-9- and p-Stat3 Tyr705-positive metastasis cells, as analyzed by IHC and western blot. Then, we used the lung and abdomen metastasis models of colon cancer to further verify this result. The number of lung metastatic nodules, the lung weight and the tumor nodules in the two metastasis models also indicated that nifuroxazide prevented the generation of lung and abdomen metastases.

Recently published studies showed that a complex multidirectional interaction exists between tumor cells surrounding the stroma and the microenvironment at metastatic sites. Moreover, infiltration and accumulation of tumor-associated myeloid cells into the lungs and other organs have a crucial role in the development of metastasis. In addition, Stat3 is constitutively activated not only in tumor cells but also in tumor endothelial and myeloid cells, including MDSCs and tumor-associated macrophages, promoting the expression of a large number of metastatic and angiogenic factors. Therefore, Stat3 is important for tumor angiogenesis and metastasis. Our in vivo studies indicated that the treatment of mice with nifuroxazide caused a significant reduction in the number of MDSCs in the spleen, blood and tumors compared with that of the vehicle group, which was also accompanied by an increased infiltration of CD8+ T cells in the tumors. Importantly, nifuroxazide markedly inhibited the number of M2-type macrophages in tumor in the abdomen metastasis model. It is therefore conceivable that nifuroxazide could potentiate the antitumor effects by stimulating the antitumor immune responses. However, in the lung metastasis model, nifuroxazide did not significantly decrease the number of MDSC in the spleen and lung compared with that of the vehicle group. We doubt that the modest lung metastasis in vivo might be due to the low dose of nifuroxazide and its pool bioavailability. Therefore, more investigations will be needed to enhance its antitumoral activities in vivo.

In conclusion, our present studies provide important information regarding the antitumoral activities of nifuroxazide in CRC. To our knowledge, this is the first study to demonstrate that the anti-CRC activities of nifuroxazide in vitro and in vivo. Mechanism studies showed that nifuroxazide could inhibit cancer cell growth and cell apoptosis via ROS-mitochondrial apoptotic pathway. Moreover, we further found that nifuroxazide markedly blocked cell migration and invasion. Importantly, nifuroxazide could inhibit metastasis by reducing the number of MDSCs and M2-type macrophages in tissues and enhancing the antitumor immune responses. Our current study further implied that Stat3 activity is important for CRC response to nifuroxazide, and Stat3 inhibition by nifuroxazide direct the proapoptotic activity on tumor cells and positive effects on tumor immunologic microenvironment. Taken together, blocking Stat3 signaling pathway with nifuroxazide may, in part, have promise in the treatment of CRC by inhibiting invasion and metastasis.
paraformaldehyde and stained with Hoechst 33342 solution (5 μg/ml). Then, the nuclear morphology of the cells was observed by fluorescence microscopy (Leica DM4000B; Leica, Wetzlar, Germany).

**Apoptotic assays.** To further investigate the apoptosis induction effects of nifuroxazide, apoptotic cells were detected by FCM. Briefly, cells (1–2×10^5 cells per well) were seeded in a 6-well plate overnight and treated with nifuroxazide. After 24 h of treatment, the cells were harvested and washed with PBS. The levels of apoptosis were examined using an Annexin V-FITC Apoptosis Detection Kit according to the manufacturer’s instructions by FCM (BD Biosciences). Data were analyzed using the FlowJo software (Tree Star, San Carlos, CA, USA).

**Measurement of ROS levels in cells.** After exposure to different concentrations of nifuroxazide for 24 h, CT26 cells were incubated with DCFH-DA (10 μM) at 37 °C for 30 min. The fluorescence intensity was measured by FCM. To further detect the changes in ROS, antioxidant treatment by 2 mM NAC (an ROS inhibitor) for 1 h was carried out before nifuroxazide exposure.

**ΔΨ_m assay.** Rh123 was used to test the changes in ΔΨ_m by FCM. In brief, cells (1–2×10^5 cells per well) were seeded in a 6-well plate overnight and treated with nifuroxazide for 24 h, and then the harvested cells were washed with cold PBS and incubated with Rh123 solution (5 μg/ml) at 37 °C for 30 min in the dark and then ΔΨ_m was measured by FCM.

**Boyd en chamber migration and invasion assay.** Modified Transwell invasion assay was conducted as described previously with minor modifications. Briefly, Matrigel (BD Biosciences) diluted 1:3 in serum-free medium was added (60 μl per well) to the upper surface of 24-well Transwell plate (Millipore, Cambridge, MA, USA). After Matrigel polymerization, the top of the Matrigel layer was seeded with 1×10^5 CT26 or HT29 cells in 100 μl serum-free medium to which with 0.1% DMSO or various concentrations of nifuroxazide were added, and the lower compartments were filled with 600 μl of the complete medium, which served as a chemoattractant. After 24 h, the cells on the top were moved with a cotton swab, and the invasion cells on the filters were stained with crystal violet after being fixed with 4% paraformaldehyde. The images were taken using a Zeiss digital microscope (Zeiss, Jena, Germany). Five independent areas per well were counted and the mean number of migrated cells was calculated. Boyd en chamber migration assay was performed according to the previous studies. A total of 1×10^5 CT26 or HT29 cells in 100 μl serum-free medium were added to the upper chamber, and the bottom chamber was filled with 600 μl of the complete medium containing 10% FBS. Both chambers were added with different concentrations of nifuroxazide. After 24 h, a cotton swab was used to discard the non-migrated cells in the upper chamber, and the migrated cells were stained with 0.5% crystal violet. In total, six random fields were counted and photographed under a light microscope.

**Flow cytometry.** At the indicated time points, we prepared single-cell suspensions of tumor, spleen, lung and blood by mechanical and enzymatic dispersion as described previously. Then, 1×10^6 freshly prepared cells were suspended in 100 μl PBS and stained with different concentration of fluorochrome-coupled antibodies to F4/80, CD206, CD11b, CD8, CD68 and Gr1. Cells were collected by FCM and data were analyzed using the FlowJo software.

**Western blot assay.** Western blot analysis was performed as described previously, with some modification. Briefly, CT26 cells were treated with nifuroxazide in different concentrations for 24 h. Harvested cells were washed two times with ice-cold PBS and lysed into RIPA buffer. Protein concentrations were examined using the Lowry method and equalized before loading. The cell samples or tumor lysates were applied to SDS-PAGE gels and transferred onto polyvinylidene difluoride membranes (Amersham Bioscience, Piscataway, NJ, USA). Next, the membranes were incubated with specific primary antibodies overnight at 4 °C, followed by horseradish peroxidase-conjugated secondary antibodies. After being incubated with secondary antibodies, the reactive bands were identified using a commercially available Enhanced Chemiluminescence Kit (Amersham Bioscience).

**Mice, tumor model and treatment.** The mice models were as described previously. To establish a pulmonary metastasis model, a total of 5×10^5 CT26 cells were injected into the tail vein of Balb/C mice. To establish an abdominal metastasis model, a total of 5×10^5 CT26 cells were intraperitoneally injected on day 6 after post-tumor inoculation, each model was randomized into three groups with eight mice in each group for further administration as follows: vehicle, group of 25 mg/kg and group of 50 mg/kg. In the abdominal metastasis model, AC was calculated before and after treatment of nifuroxazide. The animals were killed on day 12 after the first treatment. Seeding metastatic tumor nodules in the abdominal cavity were counted by naked eyes and weighted. Metastatic tumor nodules in the subpleural regions of the lung were counted under a dissecting microscope and weighted.

**Immunohistochemistry.** IHC staining of tumors sections was described previously. Paraffin-embedded tumor sections were stained with primary antibodies (MMP-9, p-Stat3, cleaved caspase-3 and Ki-67) using the DAB detection Kit (ZSGB-BIO Co., Beijing, China).

**Statistical analysis.** All experiments were performed at least in triplicate. Results are expressed as mean ± S.D. and P-values for comparison of two groups were determined by two-tailed Student’s t-test. Statistically significant P-values were labeled as follows: *P*<0.05, **P*<0.01 and ***P*<0.001.

**Conflict of Interest**

The authors declare no conflict of interest.

**Acknowledgements.** We are grateful to Weihan Yang at Merck Millipore for her helpful suggestions on the manuscript. We also thank Tao Yin for suggestions throughout the execution of this project. This research was supported by National Natural Science Foundation of China (81500054, 81402338 and 81672397) and China Postdoctoral Science Foundation (2015M570788 and 2016T08859).

**Author contributions**

Conceived and designed the experiments: TY, LY and YW. Performed the experiments: TY, FY, YL and YZ. Analyzed the data: TY, QL, XS, YX, SY and LY. Contributed reagents/materials/analysis tools: YX, LZ, NW, LZ, HG and YX. Wrote the manuscript: TY and FY.

1. Corvinus FM, Orth C, Moriggi R, Tsareva SA, Wagner S, Pfützner EB et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005; 7: 545–555.
2. Bocuk D, Wolf P, König S, Beißbarth T, Krause P. Expression of genes and pathways associated with colorectal liver metastases in an orthotopic and syngeneic mouse model. Z Gastroenterol 2015; 53: A4–A8.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2016; 66: 7–30.
4. Kusaba T, Nakaneya T, Yamazaki K, Yokota Y, Yoshizaki A, Inoue K et al. Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep 2006; 15: 1445–1451.
5. Grothey A, Van Cutsem E, Sobero A, Siena S, Falcone A, Ychou M et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 383: 303–312.
6. Ma XT, Wang S, Ye YJ, Du RY, Cui ZR, Somsouk M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 2004; 11: 1569–1573.
7. Estevez-Garcia P, Rivera F, Molina-Pinelio S, Benavent M, Gómez J, Limón ML et al. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget 2015; 6: 6151–6159.
8. Du W, Wang YC, Hong J, Su WY, Lin YW, Lu R et al. STAT3 isoforms regulate colorectal cancer cell apoptosis via reduction of mitochondrial membrane potential and generation of reactive oxygen species. J Cell Physiol 2012; 227: 2421–2429.
9. Alam SK, Yavd VK, Baisi S, Data A, Dutta SK, Bhattacharyya M et al. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ 2016; 23: 707–722.
10. Yamamoto Y, Matsui J, Matsuhashi T, Obashi H, Miyazaki K, Nakamura K et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 2014; 6: 18.
11. Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li Q et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res 2011; 71: 7226–7237.
12. Yu H, Jove R. The stats of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4: 137–145.
13. Miklosy G, Hillard TS, Turkson J. Therapeutic modulators of STAT signaling for human diseases. Nat Rev Drug Discov 2013; 12: 611–629.
14. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9: 798–809.
15. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signaling in cancer: new and unexpected biological functions. Nat Rev Cancer 2014; 14: 736–746.
16. Wu X, Tang W, Marquez RT, Li K, Highfill CA, He F et al. Overcoming chemotherapeutic resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget 2015; 7: 11708–11723.
17. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Plon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314–1321.
18. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69: 2506–2513.
19. Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y et al. MR-124 Suppresses Growth of Human Colorectal Cancer by Inhibiting STAT3. Plos One 2013; 8: e70300.
20. Spitznzer M, Roseler B, Bieffeld C, Emons G, Gaedcke J, Wolff HA et al. STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo. Int J Cancer 2014; 134: 997–1007.
21. Yu W, Xiao H, Lin J, Li C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem 2013; 56: 4402–4412.
22. Rath KS, Naiku SK, Lata P, Bid HK, Rivera BK, McCann GA et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res 2014; 74: 2316–2327.
23. Verma U, Sharma R, Gupta P, Kapoor B, Baro G, Sawhney V. New uses for old drugs: novel therapeutic options. Indian J Pharmaceutol 2005; 37: 279–287.
24. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007; 448: 645–646.
25. Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H et al. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008; 112: 5095–5102.
26. Yang F, Hu M, Lei Q, Xia Y, Zhu X, Song X et al. Nifuroxazide induces apoptosis and impairs resistance to apoptosis and anti-metastasis activity in melanoma. Scientific Rep 2016; 6: 20253.
27. Zhu Y, Ye T, Yu X, Lei Q, Yang F, Xia Y et al. Nifuroxazide exerts potent antitumor and anti-metastasis activity in melanoma. J Med Microbiol 2013; 62: 1107–1123.
28. Walker SR, Xiang M, Frank DA. Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 2014; 382: 616–621.
29. Brand S, Dambacher J, Beigel F, Olzak T, Diebold J, Otto JM et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005; 310: 117–130.
30. Hu W, Li X, Zhang C, Yang Y, Jiang J, Wu C. Tumor-associated macrophages in cancers. Clin Transl Oncol 2016; 18: 251–258.
31. Kahoul I, Tomaro-Duchesneau C, Prakash S. Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. J Med Microbiol 2013; 62: 1107–1123.
32. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495–516.
33. Wang C, Youle RJ. The role of mitochondria in apoptosis. Annu Rev Genet 2009; 43: 95–118.
34. Zeng B, Yu L, Ma L, Liu S, Li L, Xie W et al. Telikin induces apoptosis associated with the mitochondria-mediated pathway in human hepato-cellular carcinoma cells. Biol Pharm Bull 2013; 36: 1118–1125.
35. Kim AD, Kang KA, Kim HS, Kim DH, Choi YH, Lee SJ et al. A ginseng metabolite, compound K, induces autophagy and apoptosis via generation of reactive oxygen species and activation of JNK in human colon cancer cells. Cell Death Dis 2013; 4: e750.
36. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology 2012; 143: 844–857.
37. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362–374.
38. Sun Q, Chen X, Zhou Q, Burstein E, Yang S, Da J. Inhibiting cancer cell hallmarks through nuclear export inhibition. Signal Transduct Target Ther 2016; 1: 16010.
39. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239–252.
40. Paasila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285–293.
41. Couzin J. Medicine. Tracking the steps of metastasis, cancer’s menacing ballet. Science 2003; 299: 1002–1006.
42. Kujawski M, Kortylewski M, Lee HY, Herrmann A, Kay H, Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 2008; 118: 3367–3377.
43. Fu XY. STAT3 in immune responses and inflammatory bowel diseases. Cell Res 2006; 16: 214–219.
44. Xie TX, Wei D, Liu M, Gao AC, Ail Osman F, Sawaya R et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004; 23: 3550–3560.
45. Belle JJ, Petrov JC, Langlais D, Robert F, Cencic R, Shen S et al. Repression of p53-target gene Bbc3/PUMA by MYSM1 is essential for the survival of hematopoietic multipotent progenitors and contributes to stem cell maintenance. Cell Death Differ 2016; 23: 759–775.
46. Goo HF, Huang J, Shi HS, Chen XC, Wang YS. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One 2014; 9: e85789.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)